Location: Solmed Polyclinic (Zagreb), SB Medico (Rijeka)
Study Drug: Biological therapy that neutralizes the pro-inflammatory molecule IL-13, primarily responsible for symptoms of atopic dermatitis. The drug is already registered for treating atopic dermatitis in patients older than 12 years.
Main Inclusion Criteria: Children aged 6 months to 12 years diagnosed with atopic dermatitis three months or more ago, who, despite standard therapy, have insufficiently controlled disease.
Status: In preparation
Start of Patient Enrollment: September 2024.
